Lincoln Pharmaceuticals Current Share Price | Lincoln Pharmaceuticals Stock Screener
LINCOLN
Pharmaceuticals
Lincoln Pharmaceuticals Current Stock Price Today
Live Share Price NSE
₹604.85
▲
4.15 (0.69%)
Live Share Price BSE
₹606.40
▲
5.20 (0.86%)
As of September 18, 2026, the live Lincoln Pharmaceuticals share price (NSE: LINCOLN) is ₹604.85 on NSE and ₹606.40 on BSE, up 0.69% from the previous close, with shares trading between ₹597.05 and ₹612.35 in today's trading session, and a 52-week range of ₹444.20–₹758.15.
Browse LINCOLN financial statements to support your investment research.
Use the Lincoln Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Lincoln Pharmaceuticals Market Cap
₹1,248.85 Cr.
LINCOLN P/E Ratio (TTM)
13.22
Lincoln Pharmaceuticals P/B Ratio
1.68
EPS (TTM)
₹43.88
Dividend Yield
0.28%
Debt to Equity
-
LINCOLN 52 Week High
₹758.15
Lincoln Pharmaceuticals 52 Week Low
₹444.20
Operating Margin
15.00%
Profit Margin
17.82%
LINCOLN Revenue (TTM)
₹202.00
EBITDA
₹52.00
Net Income
₹36.00
Total Assets
₹890.00
Total Equity
₹758.00
Lincoln Pharmaceuticals Current Share Price Chart
Track the current Lincoln Pharmaceuticals share price and stock price with an interactive chart. Analyse LINCOLN price trends, trading volume, historical performance, and volatility across different timeframes — the complete Lincoln Pharmaceuticals stock quote in one place.
Lincoln Pharmaceuticals Company Profile - Fundamental Screener
Screen Lincoln Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for LINCOLN shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE405C01035
Lincoln Pharmaceuticals Balance Sheet Screener
Screen LINCOLN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 890 | 797 | 700 | 587 | 534 | 452 | 389 | 366 | 347 | 305 |
| Current Assets | 583 | 500 | 447 | 367 | 353 | 309 | 248 | 224 | 218 | 181 |
| Fixed Assets | 196 | 182 | 179 | 151 | 132 | 111 | 123 | 121 | 117 | 103 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 22 | 19 | 15 | 13 | 11 | 10 | 10 | 11 | 18 | 22 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 758 | 672 | 593 | 503 | 433 | 366 | 314 | 270 | 225 | 193 |
| Share Capital | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves & Surplus | 738 | 652 | 573 | 482 | 413 | 346 | 293 | 249 | 204 | 172 |
Lincoln Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Lincoln Pharmaceuticals income statement and profit fundamentals.
Analyze LINCOLN quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Lincoln Pharmaceuticals share price evaluation.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 202 | 183 | 182 | 171 | 169 | 161 | 150 | 158 | 171 | 156 | 116 | 143 | 165 | 158 | 105 |
| Expenses | 150 | 162 | 143 | 138 | 130 | 142 | 124 | 125 | 133 | 123 | 96 | 115 | 125 | 117 | 85 |
| EBITDA | 52 | 21 | 39 | 33 | 39 | 20 | 25 | 33 | 38 | 33 | 21 | 28 | 40 | 41 | 19 |
| Operating Profit % | 15.00% | 13.00% | 14.00% | 16.00% | 15.00% | 16.00% | 13.00% | 15.00% | 18.00% | 16.00% | 15.00% | 15.00% | 20.00% | 20.00% | 17.00% |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Profit Before Tax | 48 | 17 | 35 | 29 | 35 | 16 | 22 | 30 | 35 | 29 | 17 | 26 | 37 | 38 | 17 |
| Tax | 11 | 5 | 6 | 9 | 8 | 5 | 4 | 6 | 8 | 8 | 4 | 6 | 9 | 10 | 6 |
| Net Profit | 36 | 12 | 29 | 20 | 28 | 12 | 19 | 24 | 26 | 21 | 13 | 19 | 28 | 28 | 11 |
| EPS | 18.09 | 5.81 | 14.28 | 9.98 | 13.82 | 5.78 | 9.28 | 11.82 | 13.15 | 10.37 | 6.27 | 9.49 | 13.81 | 14.00 | 5.50 |
Lincoln Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen LINCOLN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 93 | 63 | 39 | 76 | 69 | 75 | 53 | 27 | 25 | 45 |
| Investing Activities | -79 | -57 | -37 | -78 | -64 | -31 | -18 | -12 | -26 | -42 |
| Financing Activities | -6 | -5 | -5 | -3 | -6 | -38 | -36 | -11 | 0 | -3 |
| Net Cash Flow | 8 | 1 | -2 | -5 | -1 | 7 | -1 | 4 | 0 | 0 |
Lincoln Pharmaceuticals Shareholding Pattern Screener
See Lincoln Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Lincoln Pharmaceuticals promoter holding and ownership changes for LINCOLN on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.53% | 49.78% |
| FII Holding | 5.19% | 4.60% | 5.00% | 5.14% | 4.72% | 4.70% | 3.93% | 3.95% |
| DII Holding | 1.09% | 0.27% | 0.01% | 0.01% | 0.01% | 0.01% | 0.05% | 0.04% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 34.70% | 36.12% | 36.64% | 36.27% | 36.26% | 36.29% | 37.36% | 37.10% |
| Other Holding | 9.24% | 9.24% | 8.59% | 8.81% | 9.23% | 9.23% | 9.13% | 9.14% |
| Shareholder Count | 28,303 | 29,396 | 31,867 | 31,784 | 32,370 | 31,026 | 31,375 | 29,967 |
Lincoln Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Lincoln Pharmaceuticals dividend history with payout and yield data.
View Lincoln Pharmaceuticals dividend details including ex-dates and amounts for LINCOLN stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.80 | 0.32% |
| 2024-March | ₹1.80 | 0.33% |
| 2023-March | ₹1.50 | 0.26% |
| 2022-March | ₹1.50 | 0.44% |
| 2021-March | ₹1.50 | 0.48% |
| 2020-March | ₹1.50 | 0.67% |
| 2019-March | ₹1.50 | 1.16% |
| 2018-March | ₹1.50 | 0.71% |
| 2017-March | ₹1.20 | 0.56% |
Lincoln Pharmaceuticals Stock Index Membership
See which indices include Lincoln Pharmaceuticals stock.
Check LINCOLN index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE INDEX BSE HC
BSE INDEX SMLCAP
Lincoln Pharmaceuticals Market Events Screener - Corporate Actions
Get Lincoln Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Lincoln Pharmaceuticals stock events that may affect LINCOLN share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | 1.11% |
| 2026-09-11 | 2026-09-11 | Dividend | ₹ 1.80 /share | -16.32% |
| 2026-08-13 | 2026-08-13 | Quarterly Result Announcement | NA | -3.23% |
| 2026-05-28 | 2026-05-28 | Quarterly Result Announcement | NA | 17.69% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 10.98% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 0.77% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -1.91% |
| 2025-09-12 | 2025-09-12 | Dividend | ₹ 1.80 /share | -7.50% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -1.87% |
| 2025-05-22 | 2025-05-22 | Quarterly Result Announcement | NA | 2.80% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -4.16% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -4.56% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -4.04% |
| 2024-09-13 | 2024-09-14 | Dividend | ₹ 1.80 /share | 27.63% |
| 2023-09-15 | 2023-09-16 | Dividend | ₹ 1.50 /share | 16.39% |
Lincoln Pharmaceuticals Competitors Screener - Peer Comparison
Screen LINCOLN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.91 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 247,470 | 85.36 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 188,872 | 86.95 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 112,608 | 24.28 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 110,352 | 33.22 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 106,298 | 95.94 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 97,281 | 29.91 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 96,652 | 25.88 | 34,145 | 5.56% | 3,503 | 57.04 |
| Lupin | 95,790 | 17.09 | 29,039 | 26.75% | 5,356 | 28.17 |
| Mankind Pharma | 94,163 | 44.87 | 14,636 | 14.85% | 1,938 | 37.57 |
Lincoln Pharmaceuticals Company Announcements - News Screener
Screen LINCOLN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-12 | Update Regarding Dispatch Of Physical Communication To Shareholders To Access Annual Report Of The Company. | - |
| 2026-09-11 | Reg. 34 (1) Annual Report. | - |
| 2026-09-11 | Notice Of 32Nd Annual General Meeting Of The Company. | - |
| 2026-08-29 | Intimation Of Book Closure And Record Date For The Purpose Of 32Nd Annual General Meeting And Final Dividend For The Financial Year 2025-26. | - |
| 2026-08-29 | Corporate Action-Fixes Book Closure For Determining The Dividend If Approved At The AGM | - |
| 2026-08-26 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-13 | Un-Audited Financial Results For Quarter Ended On 30 June 2026. | - |
| 2026-08-13 | Board Meeting Outcome for Board Meeting Outcome For Un-Audited Financial Results For The Quarter Ended On June 30 2026. | - |
| 2026-08-06 | Board Meeting Intimation for Board Meeting Intimation For Consideration And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026. | - |
| 2026-07-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-24 | Closure of Trading Window | - |
| 2026-05-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-28 | Corporate Action-Board approves Dividend | - |
| 2026-05-28 | Audited Financial Results For The Quarter And Year Ended 31St March 2026 | - |
| 2026-05-28 | Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended 31St March 2026. | - |
| 2026-05-18 | Corporate Action-Board to consider Dividend | - |
| 2026-05-18 | Board Meeting Intimation for Consideration Of Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended On March 31 2026. | - |
| 2026-05-12 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |